brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. brooklyn’s most advanced program is irx-2, a human cell-derived cytokine therapy, studying the safety and efficacy of irx-2 in patients with head and neck cancer in phase 2b. in a phase 2a clinical trial in head and neck cancer, irx-2 demonstrated an overall survival benefit. additional studies are either underway or planned in other solid tumor cancer indications. brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. for more information about brooklyn and its clinical programs, please visit www.brooklynitx.com.
Company profile
Ticker
ERNA
Exchange
Website
CEO
Allen Wolff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
SEC CIK
Corporate docs
Subsidiaries
Eterna Therapeutics LLC ...
IRS number
311103425
ERNA stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Mar 24
10-K/A
2023 FY
Annual report (amended)
18 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Departure of Directors or Certain Officers
16 Feb 24
424B3
Prospectus supplement
24 Jan 24
EFFECT
Notice of effectiveness
23 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
CORRESP
Correspondence with SEC
18 Jan 24
UPLOAD
Letter from SEC
17 Jan 24
S-8
Registration of securities for employees
16 Jan 24
Transcripts
ERNA
Earnings call transcript
2020 Q1
19 May 20
ERNA
Earnings call transcript
2019 Q4
17 Mar 20
ERNA
Earnings call transcript
2019 Q3
3 Nov 19
ERNA
Earnings call transcript
2019 Q2
12 Aug 19
ERNA
Earnings call transcript
2019 Q1
13 May 19
ERNA
Earnings call transcript
2018 Q4
20 Mar 19
ERNA
Earnings call transcript
2018 Q3
10 Nov 18
ERNA
Earnings call transcript
2018 Q2
5 Aug 18
ERNA
Earnings call transcript
2018 Q1
13 May 18
ERNA
Earnings call transcript
2017 Q4
6 Mar 18
Latest ownership filings
3
Peter Cicala
16 Feb 24
SC 13G/A
HALPERN JOHN D
31 Jan 24
SC 13G/A
Singer Nicholas Jason
19 Jan 24
4
Sanjeev Luther
3 Jan 24
4
Dorothy J Clarke
3 Jan 24
3
Sanjeev Luther
3 Jan 24
SC 13D/A
Cherington Charles
22 Dec 23
SC 13G
IAF, LLC
20 Dec 23
4
Charles Cherington
20 Dec 23
4
CURTIS W HUFF
18 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.65 mm | 8.65 mm | 8.65 mm | 8.65 mm | 8.65 mm | 8.65 mm |
Cash burn (monthly) | (no burn) | 384.00 k | 1.87 mm | 1.69 mm | 1.94 mm | 1.77 mm |
Cash used (since last report) | n/a | 2.64 mm | 12.84 mm | 11.64 mm | 13.36 mm | 12.14 mm |
Cash remaining | n/a | 6.00 mm | -4.19 mm | -2.99 mm | -4.72 mm | -3.50 mm |
Runway (months of cash) | n/a | 15.6 | -2.2 | -1.8 | -2.4 | -2.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 22 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 732.98 mm |
Total shares | 7.57 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Factor Bioscience | 4.22 mm | $0.00 |
Custard & Pitts Investment | 1.40 mm | $0.00 |
Freebird Partners | 1.05 mm | $2.96 mm |
Nicholas Jason Singer | 280.42 k | $648.00 k |
Purchase Capital | 280.42 k | $974.00 k |
Cypress Point Wealth Management | 94.38 k | $205.74 mm |
Naviter Wealth | 79.30 k | $172.87 mm |
CI Private Wealth | 51.31 k | $115.89 mm |
Sippican Capital Advisors | 28.10 k | $61.26 mm |
Vanguard | 24.90 k | $54.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jan 24 | Dorothy J Clarke | Stock Option Common Stock, par value $0.005 per share | Grant | Acquire A | No | No | 1.8 | 168,521 | 303.34 k | 168,521 |
1 Jan 24 | Sanjeev Luther | Stock Option Common Stock, par value $0.005 per share | Grant | Acquire A | No | No | 1.8 | 1,685,218 | 3.03 mm | 1,685,218 |
14 Dec 23 | Charles Cherington | Warrants Common Stock | Buy | Acquire P | No | No | 1.43 | 523,512 | 748.62 k | 523,512 |
14 Dec 23 | Charles Cherington | Warrants Common Stock | Dispose H | No | No | 3.28 | 523,512 | 1.72 mm | 0 | |
14 Dec 23 | Charles Cherington | Warrants Common Stock | Buy | Acquire P | No | No | 1.43 | 2,307,692 | 3.30 mm | 2,307,692 |
14 Dec 23 | Charles Cherington | Warrants Common Stock | Dispose H | No | No | 2.61 | 2,307,692 | 6.02 mm | 0 | |
14 Dec 23 | Charles Cherington | Warrants Common Stock | Buy | Acquire P | No | No | 0.125 | 3,125,976 | 390.75 k | 3,125,976 |